Across indications, Avastin has been used to treat more than 2.2 million patients worldwide[3]

PBRER=Periodic Benefit-Risk Evaluation Report.

Patients treated is based on the PBRER report of patient exposure, which was calculated based on the global total milligram volume sales divided by the average dose per patient per year, based on US approved indications. Average dose was based on the monthly dose multiplied by treatment duration (in months). Assumption of patient exposures from the PBRER report may not necessarily correspond to a unique patient.[3]

Drug utilization assumptions were considered in order to calculate the number of patients exposed to Avastin by indication worldwide, including US and Japan. Excluding Japan, the average body weight used worldwide was between 65-75 kg. Average dose was based on the approved dose of each indication. Note: some dose interruptions may have been accounted for per clinician discretion. In Japan, per sales assumption data, total dose was from the specific year of approval for each given indication.

Ovarian cancer data are based on recurrent OC only; Avastin is also indicated in stage III or IV OC after primary surgery, for which exposure data are not yet available.[3]

Avastin is extensively studied: Avastin FDA approvals based on 11 pivotal trials across 6 tumor types[1]

FDA approvals based on multiple endpoints[1,8]

For additional trial information, please select Efficacy from the indication drop-down menu.

OC=ovarian cancer; PFS=progression-free survival; OS=overall survival; 2L=second-line; psOC=platinum-sensitive ovarian cancer; ORR=objective response rate; prOC=platinum-resistant ovarian cancer; 1L=first-line; MCRC=metastatic colorectal cancer; CC=cervical cancer; mRCC=metastatic renal cell carcinoma; GBM=glioblastoma; nsNSCLC=non-squamous non-small cell lung cancer; GOG=Gynecologic Oncology Group; EORTC=European Organisation for Research and Treatment of Cancer.
*Endpoints studied in indications currently under orphan drug exclusivity.
In the Avastin GOG-0218 study, patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection received Avastin in combination with carboplatin and paclitaxel, followed by Avastin as a single agent.[1]
In the Avastin OCEANS study, patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who had not received prior chemotherapy in the recurrent setting or prior bevacizumab treatment received Avastin in combination with carboplatin and gemcitabine, followed by Avastin as a single agent.[1]
§In the Avastin OCEANS study, in patients with psOC who did not achieve statistically significant OS.[1]
||In the Avastin AURELIA study, patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that recurred within <6 months from the most recent platinum-based therapy received no more than 2 prior chemotherapy combinations.[1]
Avastin Study 2107, in patients with first-line MCRC, in combination with intravenous 5-fluorouracil–based chemotherapy.[1]
#Avastin Study E3200, in patients with second-line MCRC, in combination with intravenous 5-fluorouracil–based chemotherapy.[3]
**Avastin Study ML18147, in patients with second-line MCRC who had progressed on a first-line Avastin-containing regimen, in combination with fluoropyrimidine-irinotecan– or fluoropyrimidine-oxaliplatin–based chemotherapy.[3]
††TML=Treatment through Multiple Lines (first and second line).
‡‡There was no significant difference in ORR in the TML study.[1]
§§Avastin Study GOG-0240, in patients with persistent, recurrent, or metastatic CC in combination with paclitaxel and cisplatin or paclitaxel and topotecan.[1]
||||Avastin AVOREN study, in patients with mRCC, in combination with interferon alfa.[3]
¶¶There was no statistically significant difference in median OS.[1]
##Avastin EORTC Study 26101, in adult patients with recurrent, progressive GBM following prior therapy.[3]
***Avastin Study E4599, in patients with first-line, unresectable, locally advanced, recurrent, or metastatic nsNSCLC, in combination with carboplatin and paclitaxel.[1,8]

Access and choice

As the market evolves, Genentech is committed to:

  • Working with payers and providers to preserve patient access and physician choice
  • Continuing to offer patient support services

To learn more about our programs and services, visit Genentech-Access.com/Avastin or call (888) 249-4918